Identification of new candidate drugs for primary Sjögren’s syndrome using a drug repurposing transcriptomic approach

Archive ouverte

Felten, Renaud | Ye, Tao | Schleiss, Cedric | Schwikowski, Benno | Sibilia, Jean | Monneaux, Fanny | Dumortier, Hélène | Jonsson, Roland | Lessard, Christopher | Ng, Fai | Takeuchi, Tsutomu | Mariette, Xavier | Gottenberg, Jacques-Eric

Edité par CCSD ; Oxford University Press (OUP) -

International audience. Objectives To date, no immunomodulatory drug has demonstrated its efficacy in primary SS (pSS). We sought to analyse potential commonalities between pSS transcriptomic signatures and signatures of various drugs or specific knock-in or knock-down genes. Methods Gene expression from peripheral blood samples of patients with pSS was compared with that of healthy controls in two cohorts and three public databases. In each of the five datasets, we analysed the 150 most up- and downregulated genes between pSS patients and controls with regard to the differentially expressed genes resulting from the biological action on nine cell lines of 2837 drugs, 2160 knock-in and 3799 knock-down genes in the Connectivity Map database. Results We analysed 1008 peripheral blood transcriptomes from five independent studies (868 patients with pSS and 140 healthy controls). Eleven drugs could represent potential candidate drugs, with histone deacetylases and PI3K inhibitors among the most significantly associated. Twelve knock-in genes were associated with a pSS-like profile and 23 knock-down genes were associated with a pSS-revert profile. Most of those genes (28/35, 80%) were interferon-regulated. Conclusion This first drug repositioning transcriptomic approach in SS confirms the interest of targeting interferons and identifies histone deacetylases and PI3K inhibitors as potential therapeutic targets.

Suggestions

Du même auteur

Variability of Primary Sjögren's Syndrome Is Driven by Interferon α and Interferon α Blood Levels Are Associated With the Class II HLA–DQ Locus

Archive ouverte | Trutschel, Diana | CCSD

International audience. Objective: Primary Sjögren's syndrome (SS) is the second most frequent systemic autoimmune disease, affecting 0.1% of the general population. To characterize the molecular and clinical variab...

Efficacy of BAFF inhibition and B-cell depletion in non-obese diabetic mice as a spontaneous model for Sjögren’s disease

Archive ouverte | Felten, Renaud | CCSD

International audience. Introduction The therapeutic interest of targeting B-cell activating factor (BAFF) in Sjögren’s disease (SjD) can be suspected from the results of two phase II clinical trials but has not bee...

Alteration of innate lymphoid cell homeostasis mainly concerns salivary glands in primary Sjögren’s syndrome

Archive ouverte | Kawka, Lou | CCSD

International audience. Objective Innate lymphoid cells (ILCs) are a cell population implicated in the pathogenesis of various chronic inflammatory diseases, but little is known about their role in primary Sjögren’s...

Chargement des enrichissements...